Sex: M
Vaccine: COVID19, FLUX
Symptoms: Headache, Nasopharyngitis, Oxygen saturation, Oxygen saturation decreased
Clinical narrative: headaches with Tyvaso DPI increase; Oxygen saturations are dropping down to 83 to 85 percent; cold; Initial information received on 28-Oct-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves a 75 years old male patient (65 kg) who experienced headaches with Tyvaso DPI increase, cold and oxygen saturations are dropping down to 83 to 85 percent after receiving vaccines COVID-19 VACCINE and INFLUENZA VACCINE and while treated with TREPROSTINIL SODIUM [TYVASO].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Secondary Pulmonary arterial hypertension.  Concomitant medications included NINTEDANIB ESILATE (OFEV).  On 19-Sep-2022, the patient started taking TYVASO (TREPROSTINIL SODIUM) Inhalation powder , at dose of 16 ug four times a day (QID) via  inhalational route  (lot - 000275P; expiry date: 31-Oct-2023) for Secondary pulmonary arterial hypertension. On an unknown date TYVASO (TREPROSTINIL SODIUM) (lot - 000275P; expiry date: 31-Oct-2023) , the dosage was changed to 32 ug QID. On 24-Oct-2022, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination (immunization). On 24-Oct-2022, the patient received a  dose of suspect COVID-19 VACCINE not produced by Sanofi Pasteur lot number not reported via unknown route in unknown administration site for Covid-19 immunization.  On an unknown date in 2022,  the patient developed a non-serious event of  headaches with Tyvaso DPI (headache) (unknown latency) following the first dose intake  of TREPROSTINIL SODIUM. On the same night of 24-OCT-2022 , the patient developed a non-serious event of cold (nasopharyngitis) , (latency: same day) after the administration of INFLUENZA VACCINE , COVID-19 VACCINE and  (latency: 1 month 5 days)  following the first dose intake of TREPROSTINIL SODIUM.  On 25-Oct-2022 the patient developed a non-serious event of  oxygen saturations are dropping down to 83 to 85 percent (oxygen saturation decreased), 1 month 6 days following the first dose intake of TREPROSTINIL SODIUM and 1 day following the administration of INFLUENZA VACCINE and  COVID-19 VACCINE.  On an unknown date,headaches with Tyvaso DPI increased.  On an unknown date in Oct-2022, in the last two weeks from the date of report, the patient had missed a few doses of Tyvaso   Relevant laboratory test results included: Oxygen saturation - On 25-Oct-2022: 83-85 % [83-85%]  Action taken with TREPROSTINIL SODIUM (TYVASO) was unknown; action taken with  INFLUENZA VACCINE (INFLUENZA VACCINE) and COVID-19 VACCINE (COVID-19 VACCINE) was not applicable.  Corrective treatment: PARACETAMOL (TYLENOL) for Headache and 2 liters of OXYGEN (OXYGEN)  as needed for Oxygen saturation decreased; not reported for other event.  Outcome:  Recovered / Resolved on an unknown date in 2022 for the event headaches; unknown for other events.